Iterative PICC Placement Versus Long Term Device

Inclusion Criteria: * Women older than 18 years old; * Breast cancer diagnosis histologically proven , for any histological subtypes; * 4 or 6 indication of neoadjuvant or adjuvant chemotherapy; according to hormonal status and HER2 of the tumors, the patient may be treated concomitantly with hormone therapy and / or trastuzumab; Nota Bene: treatment protocol adopted will imperatively be administered in 3-week cycles. * Central venous access indication; * Ability to understand and willingness to comply with the study monitoring; * Affiliated to the French social security system; * Informed Consent dated and signed, indicating that the patient has been informed of all pertinent aspects of the study before inclusion. Exclusion Criteria: * Any contraindication for placement of a central venous catheter ( hemostasis disorders , active infection treated with antibiotics , ...); * Patient who can't stop anti -vitamin K treatment ( AVK ) ( a relay by Heparin Low Molecular Weight (LMWH) is possible); * History of central access, regardless of the indication; * Any active disease other than cancer pathology , requiring repeated administration of intravenous therapy ; * Patient deprived of liberty; * Not monitoring for social, geographical, psychological or family reason.